Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use

- PMLiVE

Otsuka files new TB candidate in Japan as shortages worsen

Delamanid shows promise in multi-drug resistant TB but supplies of rifampin are low

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

- PMLiVE

AstraZeneca veteran Deborah Hartman joins Avaxia

Will lead the development of AVX-470 in ulcerative colitis

- PMLiVE

Chiltern promotes Stuart McGuire and Jim Szymeczek

CRO fills two senior roles

- PMLiVE

Look who’s talking (2.0): How technology is shaping healthcare communications

Despite rhetoric to the contrary, the healthcare conversation has not changed - it’s only just started. Is technology helping to shift the dynamics of healthcare communications?

- PMLiVE

Another NICE rejection for Roche’s Avastin

Second draft guidance turns down drug’s use in advanced ovarian cancer

Sanofi reception

Sanofi to act as contract manufacturer for Transgene

French biopharma partners with its big pharma compatriot on long-term deal

- PMLiVE

FDA delays GlaxoSmithKline’s pandemic flu vaccine

More time needed due to "administrative" issue

- PMLiVE

AstraZeneca settles with generic rivals in Crestor patent challenge

Blocks competition in US until May 2016

- PMLiVE

Golinharris open London healthcare comms operation

Team to be led by Virgo director Siân Boisseau

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links